Login to Your Account

Other News To Note

Wednesday, August 29, 2012
• Bolder BioTechnology Inc., of Boulder, Colo., published a study showing that its long-acting inerleukin-11 analogue prevented kidney damage from ischemia reperfusion injury in mice. The research was carried out at Columbia University, and published online in the American Journal of Physiology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription